Helios Antibody (H-1): sc-390358

Helios Antibody (H-1) is a mouse monoclonal IgG2a light chain antibody that detects Helios in mouse, rat, and human samples through western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Helios (H-1) antibody recognizes a crucial member of the Ikaros family of transcription factors, which play a significant role in T cell development and activation. Helios (H-1) monoclonal antibody targets a protein primarily located in the nucleus, where Helios interacts with DNA and other transcriptional regulators to modulate gene expression essential for T cell differentiation and function. Nuclear localization of Helios enables precise control over transcriptional programs governing immune responses, particularly in T cells, where Helios helps maintain the balance between activation and tolerance. Helios forms homodimers and heterodimers with other Ikaros family members, enhancing regulatory capabilities and contributing to immune signaling pathway complexity. Anti-Helios antibody (H-1) serves as an invaluable tool for researchers studying T cell biology and immune regulation mechanisms, particularly given Helios′s influence on T cell fate decisions in normal immune function and disease pathogenesis, including autoimmune disorders and cancers.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Helios Antibody (H-1) References:

1. Helios+ and Helios- Treg subpopulations are phenotypically and functionally distinct and express dissimilar TCR repertoires.  |  Thornton, AM., et al. 2019. Eur J Immunol. 49: 398-412. PMID: 30620397
2. Helios serves as a suppression marker to reduce regulatory T cell function in pancreatic cancer patients.  |  Liu, MF., et al. 2021. Immunol Res. 69: 275-284. PMID: 33959834
3. Acute pharmacological degradation of Helios destabilizes regulatory T cells.  |  Wang, ES., et al. 2021. Nat Chem Biol. 17: 711-717. PMID: 34035522
4. Differences in Maturation Status and Immune Phenotypes of Circulating Helios+ and Helios- Tregs and Their Disrupted Correlations With Monocyte Subsets in Autoantibody-Positive T1D Individuals.  |  Zhang, Y., et al. 2021. Front Immunol. 12: 628504. PMID: 34054801
5. Germline biallelic mutation affecting the transcription factor Helios causes pleiotropic defects of immunity.  |  Shahin, T., et al. 2021. Sci Immunol. 6: eabe3981. PMID: 34826259
6. Upregulated TIGIT+ and Helios+ regulatory T cell levels in bronchoalveolar lavage fluid of NSCLC patients.  |  Lin, F., et al. 2022. Mol Immunol. 147: 40-49. PMID: 35504057
7. Co-Expression of TIGIT and Helios Marks Immunosenescent CD8+ T Cells During Aging.  |  Pieren, DKJ., et al. 2022. Front Immunol. 13: 833531. PMID: 35651622
8. Co-expression of Foxp3 and Helios facilitates the identification of human T regulatory cells in health and disease.  |  Morina, L., et al. 2023. Front Immunol. 14: 1114780. PMID: 37350974
9. Helios characterized circulating follicular helper T cells with enhanced functional phenotypes and was increased in patients with systemic lupus erythematosus.  |  Zeng, X., et al. 2024. Clin Exp Med. 24: 5. PMID: 38240853
10. KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer.  |  Santagata, S., et al. 2024. Clin Cancer Res. 30: 4755-4767. PMID: 39167621

The preferred Helios antibody is Helios Antibody (E-7): sc-390357.